ICYMI, some of this week’s featured content includes systemic treatment for pediatric AD, a new video game for dermatologists, St. Jude's registry for pediatric melanoma, and more.
New and forthcoming options bring opportunity for optimizing patient care.
Level Ex has announced its Top Derm Game as its expansion into the dermatology specialty.
St. Jude Children’s Research Hospital researchers have created a registry to better understand pediatric melanoma.
Alma today announces the FDA clearance of its Alma Hybrid combination platform, which includes an ablative 10,600 nm (CO2) laser and nonablative 1570 nm laser for skin resurfacing.
Engage patients in treatment compliance and lifestyle changes to achieve optimal outcomes.
In this month's Legal Eagle column, David J. Goldberg, MD, JD, explores chat room referrals and how they could possibly alter the physician-patient relationship.
The FDA has decided to delay the PDUFA goal date for baricitinib for treatment of adults with moderate to severe atopic dermatitis.
Addressing underdiagnosis, underrepresentation, and undertreatment in skin of color patients with psoriasis.
The FDA did not meet the PDUFA goal date for abrocitinib (PF-04965842; Pfizer), a potential treatment of moderate to severe atopic dermatitis in adults and adolescents.
Christoper Bunick, MD, PhD, provides an update on benzene contamination in sunscreen, including a recent recall from Johnson & Johnson.
In this month's Cosmetic Conundrums column, Dermatology Times® Chief Medical Editor Zoe Diana Draelos, MD, explores the world of eyebrows, including microblading, grooming, and shape.
Gastrointestinal infections were the most common serious infections associated with biologics, according to a cohort analysis.
This week’s edition of The Mainstream Patient features stories about a new TikTok-inspired acne treatment, skin care ingredient absorption, injectable psoriasis treatments, plus more.